Galmed Pharmaceuticals GLMD Stock
Galmed Pharmaceuticals Price Chart
Galmed Pharmaceuticals GLMD Financial and Trading Overview
| Galmed Pharmaceuticals stock price | 1.94 USD |
| Previous Close | 3.72 USD |
| Open | 3.64 USD |
| Bid | 0 USD x 1200 |
| Ask | 0 USD x 1400 |
| Day's Range | 3.6 - 4.23 USD |
| 52 Week Range | 0.29 - 5.63 USD |
| Volume | 17.62K USD |
| Avg. Volume | 228.06K USD |
| Market Cap | 6.27M USD |
| Beta (5Y Monthly) | 1.112323 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 69.72 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GLMD Valuation Measures
| Enterprise Value | -5901537 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.51805556 |
| PEG Ratio (5 yr expected) | -0.03 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.5227018 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.436 |
Trading Information
Galmed Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 1.112323 |
| 52-Week Change | 745.80% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 5.63 USD |
| 52 Week Low | 0.29 USD |
| 50-Day Moving Average | 2.24 USD |
| 200-Day Moving Average | 0.91 USD |
GLMD Share Statistics
| Avg. Volume (3 month) | 228.06K USD |
| Avg. Daily Volume (10-Days) | 11.26K USD |
| Shares Outstanding | 1.68M |
| Float | 1.36M |
| Short Ratio | 0.26 |
| % Held by Insiders | 13.83% |
| % Held by Institutions | 10.78% |
| Shares Short | 16.05K |
| Short % of Float | 1.11% |
| Short % of Shares Outstanding | 0.94% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -37.67% |
| Return on Equity (ttm) | -74.55% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -13527000 USD |
| Net Income Avi to Common (ttm) | -13553000 USD |
| Diluted EPS (ttm) | -7.34 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 12.15M USD |
| Total Cash Per Share (mrq) | 7.23 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 4.582 |
| Book Value Per Share (mrq) | 7.136 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -14744000 USD |
| Levered Free Cash Flow (ttm) | -9880625 USD |
Profile of Galmed Pharmaceuticals
| Country | United States |
| State | N/A |
| City | Tel Aviv |
| Address | 16 Tiomkin Street |
| ZIP | 6578317 |
| Phone | 972 3 693 8448 |
| Website | https://www.galmedpharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 4 |
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.
Q&A For Galmed Pharmaceuticals Stock
What is a current GLMD stock price?
Galmed Pharmaceuticals GLMD stock price today per share is 1.94 USD.
How to purchase Galmed Pharmaceuticals stock?
You can buy GLMD shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Galmed Pharmaceuticals?
The stock symbol or ticker of Galmed Pharmaceuticals is GLMD.
Which industry does the Galmed Pharmaceuticals company belong to?
The Galmed Pharmaceuticals industry is Biotechnology.
How many shares does Galmed Pharmaceuticals have in circulation?
The max supply of Galmed Pharmaceuticals shares is 1.66M.
What is Galmed Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Galmed Pharmaceuticals PE Ratio is 0.02782559 now.
What was Galmed Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Galmed Pharmaceuticals EPS is 69.72 USD over the trailing 12 months.
Which sector does the Galmed Pharmaceuticals company belong to?
The Galmed Pharmaceuticals sector is Healthcare.
Galmed Pharmaceuticals GLMD included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 18350.19 USD — |
-2.64
|
7.23B USD — | 18216.63 USD — | 18992.3 USD — | — - | 7.23B USD — |
| NASDAQ Capital Market Composite RCMP | 102.02 USD — |
-3.29
|
— — | 101.66 USD — | 107.21 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 993.66 USD — |
-1.66
|
— — | 990.15 USD — | 1016.8 USD — | — - | — — |
| NASDAQ Composite Total Return I XCMP | 22440.37 USD — |
-2.64
|
— — | 22277.04 USD — | 23225.6 USD — | — - | — — |
- {{ link.label }} {{link}}